ITB Therapy^SM And Multiple Sclerosis

Pam B. Living with multiple sclerosis receiving ITB Therapy since 2004

It is reported that 34% of people with MS have spasticity that interfered with daily living.⁴ Managing severe spasticity with Medtronic ITB Therapy^SM (Intrathecal Baclofen Therapy) in people with spinal-origin spasticity, including MS:

• Results in significant decrease in Ashworth and Spasm scores^9,10,32,36
• Results in improved function, as shown by statistically significant improvement in Functional Independence Measure scores^32,33
• Improves functional ability in bathing, dressing lower body, and transfers³³
• Demonstrated the highest satisfaction rating compared to all oral treatments⁴
• May result in significantly less spasticity and fewer painful spasms compared with those treated with oral medications only⁴
• Significantly reduces spasticity-related pain^35,36
• May help retain ambulatory function³⁶

See the Clinical Evidence in Hypertonia Associated with MS section for more information on these studies and their outcomes. 

The Consortium of Multiple Sclerosis Centers developed an online program, titled Evaluation and Management of Spasticity in Multiple Sclerosis, to support educational efforts on advanced spasticity in MS and available treatment options including rehabilitation, oral medication, local injections, and surgical interventions. You may view the program, at no charge, at www.mscare.org/spasticityteam.

©Medtronic, Inc. 2008                                                   • Contact Medtronic • Privacy Statement • Terms of Use • Site Map